Following a full submission:
relugolix (Orgovyx®) is accepted for use within NHSScotland.
Indication under review:
• for the treatment of adult patients with advanced hormone-sensitive prostate cancer
• for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
• as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
In an open-label, randomised phase III study, there was a significantly higher sustained castration rate in patients with advanced hormone-sensitive prostate cancer treated with relugolix compared with a gonadotrophin releasing hormone (GnRH) agonist for 48 weeks.
Medicine details
- Medicine name:
- relugolix (Orgovyx)
- SMC ID:
- SMC2678
- Indication:
- For the treatment of adult patients with advanced hormone-sensitive prostate cancer.
- For the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
- As neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.- Pharmaceutical company
- Accord Healthcare
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 October 2024